Tissue distribution and interindividual variation in human UDP-glucuronosyltransferase activity: relationship between UGT1A1 promoter genotype and variability in a liver bank.
The variability in a liver bank and tissue distribution of three probe UDP-glucuronosyltransferase (UGT) activities were determined as a means to predict interindividual differences in expression and the contribution of extrahepatic metabolism to presystemic and systemic clearance. Formation rates of acetaminophen-O-glucuronide (APAPG), morphine-3-glucuronide (M3G), and oestradiol-3-glucuronide (E3G) as probes for UGT1A6, 2B7, and 1A1, respectively, were determined in human kidney, liver, and lung microsomes, and in microsomes from intestinal mucosa corresponding to duodenum, jejunum and ileum. While formation of E3G and APAPG were detectable in human kidney microsomes, M3G formation rates from kidney microsomes approached the levels seen in liver, indicating significant expression of UGT2B7. Interestingly, rates of E3G formation in human intestine exceeded the hepatic rates by several fold, while APAPG and M3G formation rates were low. The intestinal apparent Km value for E3G formation was essentially identical to that seen in liver, consistent with intestinal UGT1A1 expression. No UGT activities were observed in lung. Variability in APAPG and M3G activity across a bank of 20 human livers was modest (< or = 7-fold), compared to E3G formation, which varied approximately 30-fold. The E3G formation rates were found to segregate by UGT1A1 promoter genotype, with wild-type (TA)6 rates significantly greater than homozygous mutant (TA)7 individuals. Kinetic analyses were performed to demonstrate that the promoter mutation altered apparent Vmax without significantly affecting apparent Km. These results suggest that glucuronidation, and specifically UGT1A1 activity, can profoundly contribute to intestinal first pass metabolism and interindividual variability due to the expression of common allelic variants.
Fisher
M B
MB
Department of Drug Disposition, Eli Lilly and Co., Indianapolis, IN 46285, USA.
Vandenbranden
M
M
Findlay
K
K
Burchell
B
B
Thummel
K E
KE
Hall
S D
SD
Wrighton
S A
SA
D000082:Acetaminophen / Q000031:analogs & derivatives* / Q000378:metabolism; D000408:Alamethicin / Q000378:metabolism; D000483:Alleles; D004958:Estradiol / Q000031:analogs & derivatives / Q000378:metabolism; D014644:Genetic Variation; D005838:Genotype; D014453:Glucuronosyltransferase / Q000235:genetics*; D006720:Homozygote; D006801:Humans; D007422:Intestines / Q000201:enzymology; D007668:Kidney / Q000201:enzymology; D007700:Kinetics; D008099:Liver / Q000201:enzymology*; D008168:Lung / Q000201:enzymology; D008657:Metabolic Clearance Rate; D008862:Microsomes, Liver / Q000201:enzymology; D009020:Morphine / Q000378:metabolism; D009022:Morphine Derivatives / Q000378:metabolism; D009154:Mutation; D011401:Promoter Regions, Genetic; D014015:Tissue Banks; D014018:Tissue Distribution
D009022:Morphine Derivatives; C025482:estradiol-3-glucuronide; D000408:Alamethicin; D000082:Acetaminophen; D004958:Estradiol; D009020:Morphine; C037386:acetaminophen glucuronide; D014453:Glucuronosyltransferase; C018108:morphine-3-glucuronide